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Abstract
Background: The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic
control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart
disease (CHD) and type 2 diabetes mellitus (T2DM).
Methods: According to the research design, a randomized, double-blind, placebo-controlled trial has been
implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2
groups for taking placebo (n = 30) or 250mg magnesium oxide plus 150mg zinc sulfate (n = 30) for 12 weeks.
Results: Magnesium and zinc significantly decreased fasting plasma glucose (FPG) (β − 9.44mg/dL, 95% CI, − 18.30, −
0.57; P = 0.03) and insulin levels (β − 1.37 μIU/mL, 95% CI, − 2.57, − 0.18; P = 0.02). Moreover, HDL-cholesterol levels
significantly enhanced (β 2.09mg/dL, 95% CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an
association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (β − 0.85mg/L,
95% CI, − 1.26, − 0.45; P < 0.001), a significant increase in total nitrite (β 5.13 μmol/L, 95% CI, 1.85, 8.41; P = 0.003) and
total antioxidant capacity (TAC) (β 43.44 mmol/L, 95% CI, 3.39, 83.50; P = 0.03) when compared with placebo.
Furthermore, magnesium and zinc significantly reduced the Beck Depression Inventory index (BDI) (β − 1.66; 95% CI, −
3.32, − 0.009; P = 0.04) and Beck Anxiety Inventory (BAI) (β − 1.30; 95% CI, − 2.43, − 0.16; P = 0.02) when compared with
the placebo.
Conclusions: In patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on
FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. This suggests that magnesium and
zinc co-supplementation may be beneficial for patients with T2DM and CHD. Further studies on more patients and
lasting longer are needed to determine the safety of magnesium and zinc co-supplementation.
Trial registration: Current Controlled Trials http://www.irct.ir: IRCT20130211012438N31 at 11 May 2019 of registration.
This study retrospectively registered.
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Background
As reported by the World Health Organization (WHO),
coronary heart disease (CHD) is a primary cause of both
men and women’s mortality, which results in more than 7
million deaths annually [1]. It is widely accepted that type
2 diabetes mellitus (T2DM) is also one of the important
risk factors for CHD. The risk of CHD in patients with
diabetes is double as high as in non-diabetic subjects [2].
Many studies have shown that there is a correlation be-
tween CHD and metabolic syndrome (MetS), T2DM, and
elevated levels of inflammatory and oxidative stress bio-
markers [3, 4]. Some researches indicated that levels of
magnesium and zinc are significantly decreased in patients
suffering from CHD and T2DM [5, 6].
It has been already reported that there are beneficial
impacts of trace elements on the metabolic profile in the
patients suffering from metabolic disorders [7–9]. For
example, Asemi et al. showed that magnesium supple-
mentation with a dose of 250 mg per day in the form of
magnesium oxide to the pregnant females suffering from
gestational diabetes (GDM) considerably improved gly-
cemic control and lipoproteins as well as oxidative stress
and inflammation biomarkers [7]. Zinc supplementation
at a dose of 30 mg per day in the form of zinc sulfate by
subjects with pre-diabetes for 6 months caused a
significant improvement in glycemic control [10]. It was
reported that co-supplementation is possibly more ef-
fective when compared to single element supplementa-
tion [11]. A recent study on patients with T2DM
indicated that zinc, magnesium, vitamin C and E co-
supplementation significantly reduced fasting plasma
glucose (FPG) and malondialdehyde (MDA) levels and
considerably increased the levels of HDL-cholesterol
[12]. Results also showed that zinc and magnesium co-
supplementation to females suffering from polycystic
ovary syndrome (PCOS) improved high sensitivity C-
reactive protein (hs-CRP) as well as total antioxidant
capacity (TAC); however, it had no effect on the other
markers of oxidative stress [13]. Magnesium-zinc-
calcium-vitamin D co-supplementation in the patients
with PCOS showed that there is an association between
such a co-supplementation and a significant improve-
ment in insulin levels, quantitative insulin sensitiveness
check index (QUICKI), inflammatory markers, decrease
in plasma triglycerides, total cholesterol and VLDL-
cholesterol and homeostatic model of insulin resistance
(HOMA-IR), without any significant influence on the
level of fasting glucose, HDL-cholesterol, and LDL-
cholesterol [14].
Both zinc and magnesium contribute substantially to
the glucose homeostasis and lipoprotein metabolism.
Magnesium participates as a cofactor in different adeno-
sine triphosphate depended reactions which are import-
ant in carbohydrate metabolism and insulin action [15].
Magnesium also contributes to lipoprotein metabolism
by modulating the 3-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA) reductase enzyme [16]. Some studies also
demonstrated that zinc affected glucose homeostasis in
terms of formation, storage, and secretion of insulin
[17–20]. It seems that magnesium could have anti-
inflammatory properties having antagonist effects to
calcium which contributes significantly to the inflamma-
tion, transmembrane ion transport, and protein synthesis
[21] as well as increasing production of prostacyclins
[22]. Moreover, zinc can decrease inflammation and oxi-
dative damage having beneficial effects on hemostasis by
influencing coagulation and platelet accumulation [23],
and reducing the activity of calcium channels. Also, cal-
cium uptake defect and impaired second-messenger
function results from an abnormal sulfhydryl redox state
in the membrane channel protein may have an impact
on cardiovascular disease (CVD) [24].
There is a lot of literature focused on the effects of co-
administration of zinc and magnesium in patients with
CHD or T2DM and the management of insulin resist-
ance, serum lipoproteins, oxidative damage and inflam-
mation in these patients. No study so far has evaluated
the role of zinc and magnesium co-supplementation in
patients with CHD and T2DM and there is insufficient
evidence to recommend such a combined supplementa-
tion for these patients. Therefore, the aim of this study
was to analyze the effects of combination of magnesium
and zinc supplementation on inflammation biomarkers,
metabolic profile, and oxidative stress but also some
mental health parameters in patients suffering from
CHD and T2DM.
Methods
Study population
This was a double-blind, randomized placebo-
controlled research, which was registered in the Iranian
registry of clinical trials at http://www.irct.ir: no,
IRCT20130211012438N31. This research was done at
the cardiology clinic, which is affiliated to Kashan Uni-
versity of Medical Sciences (KAUMS), Kashan, and
Iran. It lasted from January 2019 to May 2019. The
study was performed following the Declaration of
Helsinki principles. The research design was approved
by the Research Ethics Committee of KAUMS (no.
IR.KAUMS.MEDNT.REC.1397.079), Iran. Each patient
signed a written informed consent. The criteria for in-
cluding in the study were: patients suffering from T2DM
in the age ranging between 40 and 95 years with proven 2-
and 3-vessel CHD, and no smoking. T2DM and CHD
diagnosis was made based upon American Diabetes Asso-
ciation criteria [25] and the American Heart Association
criteria [26]. Some patients were excluded based on the
following criteria: taking any type of supplements such as
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magnesium and/or zinc 3months before the study, con-
suming antioxidant and or anti-inflammatory supplements
and/or omega-3 fatty acids, proven renal or hepatic failure,
acute myocardial infarction, or cardiac surgery in the last
3 months, thyroid disease, any change in LDL levels after
the 6-week intervention, infection, unwillingness to co-
operate, and antibiotic use during study.
Research design
Patients were randomly assigned into 2 treatment
groups (after strafication based on baseline BMI and age):
one taking 250mg per day magnesium (magnesium oxide)
and 150mg/day zinc (zinc sulfate) containing 30mg elem-
entary zinc or placebo (starch) (Barij Essence; Kashan: Iran)
(n = 30 in each group) for 12 weeks. Due to the lack of evi-
dence about the appropriate dosage and duration of zinc
and magnesium co-supplementation for subjects with
T2DM and CHD, the above-mentioned dose and duration
of zinc and magnesium used based on previous studies in
patients with PCOS [13] and pre-diabetes [10]. Color, form,
size, and package of the placebo and magnesium plus zinc
supplements were similar. Randomizing has been done by
computer-generated random numbers. The investigators
and patients have been blinded concerning the
randomization and supplements/placebo until the final ana-
lyses have been made. Enrolling the patients, randomizing,
and assigning them to the treatment or placebo have been
performed by the qualified personnel at the clinic. Compli-
ance with taking placebo and the supplement has been
made by examining the capsule containers. Each patient
filled in the three-day dietary intake record at 1, 6, and 12
weeks of the trial. The dietary records were filled in accord-
ing to estimated values household measurements. Nutri-
tionist IV software (First Databank; San Bruno; CA)
adapted for the Iranian food pattern has been employed to
achieve the patients’ nutrient intakes in accordance with
three-day food records. Patients weight (using Seca; Ham-
burg: Germany balance) to the nearest 0.1 kg and height
(using Seca; Hamburg: Germany) to the nearest 0.1 cm
were measured at baseline and 12 weeks after clinical inter-
vention. BMI was calculated. All anthropometric measure-
ments were done by a qualified nutritionist.
Assessment of biochemical variables
The primary outcome was insulin resistance and other
metabolic parameters were secondary outcomes.
According to research design, fasting blood samples (10
mL) have been drawn out at the baseline and after a 12-
week period of intervention at Kashan Reference
Laboratory. Blood was collected in 2 separate tubes: 1) one
without EDTA and trace mineral free to separate the serum
and to quantify serum magnesium, zinc, insulin, lipids and
CRP and 2) another containing EDTA to measure plasma
total nitrite and biomarkers of oxidative stress. Serum
insulin was assessed using ELISA kit (DiaMetra; DKO076
code, Milano: Italy) through inter- and intra-assay coeffi-
cient variances (CVs) beneath 5%. QUICKI and HOMA-IR
were evaluated on the basis of the standard formulation
[27]. Enzymatic kits (Pars Azmun; Tehran: Iran) were used
to estimate serum magnesium, zinc, FPG, serum lipopro-
teins that had inter-assay and intra-assay CVs beneath 5%.
CRP levels were evaluated using an ELISA kit (LDN; DM
E-4600 Tags code, Nordhorn: Germany) with inter-assay
and intra-assay CVs below 7%. Total nitrite were deter-
mined by Griess assay [28] and TAC by the technique pub-
lished by Benzie and Strain [29] with inter-assay and intra-
assay CVs lower than 5%. Total glutathione (GSH) was de-
termined using the procedure described by Beutler et al.
[30] and MDA by a spectrophotometric method [31] with
inter-assay and intra-assay CVs lower than 5%.
Clinical evaluation
According to the protocol of the study, the Beck Depres-
sion Inventory (BDI) has been evaluated by a modified
questionnaire [32]. Anxiety has been gauged by the Beck
Anxiety Inventory (BAI) designed by Beck et al. [33].
Statistical procedures and size of the sample
According to the research design, the sample size for-
mula has been employed for the randomized clinical
trial, in which type 1 (α) and type 2 errors (β) have been
0.05, and 0.20 (power = 80%). One of the studies per-
formed in this topic applied 0.80 as the SD and 0.64 as
the changes in the mean (d) of HOMA-IR [7]. HOMA-
IR chose to estimate sample size because it was the most
important outcome in subjects with T2DM and CVD.
Considering the power analysis, 25 subjects were re-
quired in each group. Upon the 20% drop-outs in each
group, the size of the sample has been 30 subjects.
Kolmogorov-Smirnov statistic was employed to con-
trol data normality. Independent-sample t-test has been
used for determining the difference in the anthropomet-
ric measures and dietary intake between the two groups.
Multiple linear regression model was employed to evalu-
ate the treatment impacts on the research outputs after
setting for baseline values of the biochemical parameters.
The effect size was provided as the mean difference with
95% confidence interval. Then, Pearson Chi-square test
was used to compare categorical variables. P-values less
than 0.05 were considered significant. Afterwards,
SPSS18 (SPSS Inc.; Chicago, Illinois: USA) have been
used for statistical analysis of the present trial.
Results
Fifty-five females [magnesium plus zinc (n = 27) and pla-
cebo (n = 28)] participated in the trial (Fig. 1). The com-
pliance rate was high; both groups took > 90% of
capsules during this trial. There was no adverse effects
Hamedifard et al. Lipids in Health and Disease          (2020) 19:112 Page 3 of 9
in the group of T2DM patients with CHD when taking
magnesium plus zinc supplement.
There was no significant difference between the two
groups regarding mean body height, weight, age, and
body mass index (Table 1).
Macronutrient and micronutrient ingestion as com-
puted on the basis of the three-day food records did not
differ significantly between magnesium plus zinc group
and the controls (Supplementary file 1).
Magnesium and zinc co-supplementations significantly
reduced FPG (β − 9.44 mg/dL, 95% CI, − 18.30, − 0.57;
P = 0.03) and insulin levels (β − 1.37 μIU/mL, 95% CI, −
2.57, − 0.18; P = 0.02), and significantly increased the
levels of HDL-cholesterol (β 2.09 mg/dL, 95% CI, 0.05,
4.13; P = 0.04) when compared with the placebo group
(Table 2). Magnesium plus zinc taking was associated
with a significant decrease in CRP (β − 0.85 mg/L, 95%
CI, − 1.26, − 0.45; P < 0.001), and a significant increase in
total nitrite (β 5.13 μmol/L, 95% CI, 1.85, 8.41; P = 0.003)
and TAC (β 43.44 mmol/L, 95% CI, 3.39, 83.50; P = 0.03)
when compared with the placebo group. Magnesium
and zinc co-supplementation also significantly decreased
BDI (β − 1.66; 95% CI, − 3.32, − 0.009; P = 0.04) and BAI
scores (β − 1.30, 95% CI, − 2.43, − 0.16; P = 0.02) when
compared with the placebo group. Magnesium and zinc
co-supplementation did not have any significant effects
on the other metabolic parameters when compared with
the placebo group.
Fig. 1 Summary of patient flow diagram
Table 1 General characteristics of study participants at baseline study
Placebo group
(n = 28)
Magnesium plus zinc group
(n = 27)
Pa
Age (y) 62.6 ± 10.8 61.7 ± 9.4 0.74
Height (cm) 159.5 ± 10.9 162.1 ± 7.8 0.32
Weight at study baseline (kg) 76.9 ± 12.6 81.3 ± 11.7 0.19
Weight at end-of-trial (kg) 77.0 ± 12.5 80.9 ± 11.4 0.23
Weight change (kg) 0.1 ± 1.2 −0.4 ± 1.0 0.12
BMI at study baseline (kg/m2) 30.2 ± 3.7 30.9 ± 3.8 0.47
BMI at end-of-trial (kg/m2) 30.2 ± 3.8 30.8 ± 3.7 0.59
BMI change (kg/m2) 0.03 ± 0.5 −0.1 ± 0.4 0.10
Data are means± SDs
aObtained from independent t-test
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Discussion
This study demonstrated that magnesium plus zinc sup-
plementation to subjects suffering from CHD and
T2DM had beneficial effects on FPG, insulin, HDL-
cholesterol, CRP, total nitrite, TAC, BDI and BAI scores.
However, it must be kept in mind that although the dif-
ference in few variables including FPG and HDL-
cholesterol in this study was statistically significant, it
was not clinically significant. Long-term interventions
with magnesium plus zinc supplementation might result
in greater changes in FPG and HDL-cholesterol levels.
Impact of magnesium plus zinc supplementation on
glycemic control and lipoproteins
This study showed that magnesium plus zinc supple-
ments in subjects with CHD and T2DM during 12 weeks
caused a significant decrease in FPG and insulin levels,
and significant increase in HDL-cholesterol, but it had
no effect on the HOMA-IR, QUICKI, total cholesterol,
triglycerides, VLDL-cholesterol and LDL-cholesterol
levels. According to previous studies, chronic hypergly-
cemia and dyslipidemia due to increasing insulin
resistance and inflammatory cytokines increase the risk
of diabetic and atherogenic complications [34, 35]. Earl-
ier, it was reported that nutritional supplements have
the beneficial effects on metabolic profiles [8, 36]. A
meta-analysis indicated that magnesium intake is associ-
ated with a significant improvement in FPG, triglycer-
ides, HDL-cholesterol and LDL-cholesterol levels [37].
In a study on pregnant women with GDM who were
taking as a supplement magnesium oxide (250mg/day)
during 6 weeks, a significant improvement in the FPG,
insulin concentration, HOMA-IR, QUICKI, and triglyc-
erides levels occurred, but it caused no change in other
serum lipoproteins [7]. However, magnesium lactate in a
dose of 360 mg per day during 12 weeks did not have
significant effects on HbA1c, FPG, insulin levels,
HOMA-IR and lipid profiles in normomagnesemic pa-
tients with T2DM [38]. One meta-analysis showed that
supplementing zinc to patients with T2DM has been as-
sociated with a considerable decrease of FPG, HbA1c,
total cholesterol, and a significant increase of HDL-
cholesterol, but there has been no significant association
with triglycerides [39]. Another study performed by
Table 2 The effect of combined magnesium and zinc supplementation on metabolic status in patients with T2DM and CHD
Variables Placebo group (n = 28) Magnesium and zinc group
(n = 27)
Difference in outcome measures between magnesium
and zinc treatment groupsa
Baseline Week 12 Baseline Week 12 β (95% CI) Pb
Magnesium (mg/dL) 1.84 ± 0.22 1.83 ± 0.25 1.94 ± 0.21 2.08 ± 0.22 0.15 (0.08, 0.22) < 0.001
Zinc (μg/dL) 93.3 ± 24.8 95.8 ± 25.9 98.1 ± 22.5 116.5 ± 21.5 16.21 (11.98, 20.44) < 0.001
FPG (mg/dL) 123.7 ± 31.4 128.4 ± 32.7 119.2 ± 38.0 115.6 ± 28.7 −9.44 (−18.30, −0.57) 0.03
Insulin (μIU/mL) 13.8 ± 4.5 13.9 ± 4.4 12.9 ± 5.1 11.7 ± 4.9 −1.37 (−2.57, −0.18) 0.02
HOMA-IR 4.2 ± 1.8 4.2 ± 1.7 3.7 ± 1.7 3.4 ± 1.8 −0.36 (− 0.75, 0.02) 0.06
QUICKI 0.31 ± 0.02 0.31 ± 0.02 0.32 ± 0.02 0.32 ± 0.02 0.006 (−0.002, 0.01) 0.12
Triglycerides (mg/dL) 123.7 ± 50.7 124.9 ± 46.5 128.2 ± 55.7 134.6 ± 53.9 5.66 (−5.40, 16.73) 0.30
VLDL-cholesterol (mg/dL) 24.7 ± 10.1 24.9 ± 9.3 25.6 ± 11.1 26.9 ± 10.8 1.10 (−1.08, 3.34) 0.30
Total cholesterol (mg/dL) 147.3 ± 35.3 145.6 ± 31.0 137.1 ± 28.3 140.7 ± 32.5 3.72 (−5.26, 12.71) 0.41
LDL-cholesterol (mg/dL) 77.2 ± 29.5 76.6 ± 26.5 70.8 ± 22.4 71.6 ± 25.7 0.13 (−8.32, 8.59) 0.97
HDL-cholesterol (mg/dL) 45.3 ± 7.7 43.9 ± 7.0 40.6 ± 8.4 42.1 ± 8.2 2.09 (0.05, 4.13) 0.04
Total−/HDL-cholesterol ratio 3.3 ± 0.8 3.3 ± 0.7 3.4 ± 0.7 3.4 ± 0.8 −0.06 (−0.30, 0.17) 0.59
CRP (mg/L) 3.0 ± 1.0 3.2 ± 1.2 2.7 ± 1.7 2.1 ± 1.3 −0.85 (−1.26, − 0.45) < 0.001
Total nitrite (μmol/L) 49.8 ± 6.1 48.7 ± 6.1 43.7 ± 5.3 50.1 ± 6.5 5.13 (1.85, 8.41) 0.003
TAC (mmol/L) 898.4 ± 168.4 894.9 ± 178.9 940.9 ± 107.2 976.8 ± 105.3 43.44 (3.39, 83.50) 0.03
GSH (μmol/L) 508.3 ± 72.9 524.9 ± 95.3 556.8 ± 92.9 578.2 ± 56.3 29.49 (−8.83, 67.82) 0.12
MDA (μmol/L) 2.2 ± 0.6 2.2 ± 0.5 1.9 ± 0.4 1.8 ± 0.4 −0.15 (−0.32, 0.007) 0.05
BDI score 19.7 ± 5.8 19.6 ± 5.7 21.7 ± 4.7 19.6 ± 4.9 −1.66 (−3.32, −0.009) 0.04
BAI score 15.7 ± 4.3 14.1 ± 4.8 17.0 ± 5.3 14.0 ± 5.1 −1.30 (−2.43, −0.16) 0.02
Data are mean ± SDs
BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, CHD coronary heart disease, FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis
model of assessment-estimated insulin resistance, CRP C-reactive protein, MDA malondialdehyde, QUICKI quantitative insulin sensitivity check index, T2DM type 2
diabetes, TAC total antioxidant capacity
a”Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcome’s measures
between treatment groups (magnesium and zinc group = 1 and placebo group = 0)]
bObtained from multiple regression model (adjusted for baseline values of each biochemical variables)
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Islam et al. showed that zinc supplementation (30 mg
per day of zinc sulphate) during 6 months improved
FPG, insulin resistance, insulin sensitivity and decreased
triglycerides levels without causing any significant
changes in LDL-cholesterol and HDL-cholesterol [10]. A
combination of magnesium-zinc-calcium-vitamin D dur-
ing a 12 week period has been associated with a signifi-
cant decrease of HOMA-IR, insulin, triglycerides, total
cholesterol, and VLDL-cholesterol and a significant in-
crease in the QUICKI scores, but it has not been accom-
panied by changes in LDL-cholesterol, FPG, and HDL-
cholesterol in the PCOS patients [14]. Hyper-
insulinemia and insulin resistance have been related to
hyperglycemia which is the main symptom of T2DM.
Hyperglycemia affects the glycation of lipoproteins but
has a lot of other unfavorable effects which cause accel-
erated atherosclerosis [40, 41]. Magnesium is one of the
crucial cofactors in the enzymatic processes that require
adenosine triphosphate and kinase, and therefore it plays
an important role in glucose metabolic pathways [15,
42]. Magnesium also contributes to lipoprotein metabol-
ism by modulating HMG-CoA reductase enzyme [16].
Zinc is involved in a range of functions including insulin
receptor signal transduction, secretion and tissues/or-
ganelle distribution, and inhibition of protein tyrosine
phosphatases [17, 43, 44]. Zinc may increase glucose
transport into the cells by increasing phosphorylation of
the β subunit of the insulin receptor and enhancing the
activation of phosphatidylinositol 3 kinase and protein
kinase B or Akt [45]. Furthermore, few zinc transporters
(such as ZnT8) are important for the structure, secretion
and compartmentalization of insulin in beta-cells of pan-
creas [46]. Zinc also stimulates IRAP molecule, which in
turn enables the translocation of GLUT4 to the cell
surface and enables the transport of glucose into the
cell [47]. Zinc plays an important role in the
stabilization of insulin hexamers and the pancreatic
storage of insulin as well [43].
Effects of magnesium plus zinc supplementation on
oxidative stress and inflammation
This study showed a significant decrease of CRP and a
significant increase of TAC and total nitrite as a result
of combined magnesium and zinc supplementation to
the patients with CHD and T2DM during a 12 weeks
period. Oxidative stress and inflammation because of de-
veloping micro- and macrovascular complications are
important risk factors for diabetes and diabetes-
associated atherosclerosis [48]. Asemi et al. study indi-
cated that magnesium supplement.
(250 mg/day of magnesium oxide) in pregnant women
with GDM during 6 weeks significantly decreased hs-
CRP, but there were no significant changes in TAC and
GSH concentrations [7]. Nevertheless, magnesium
supplement (magnesium oxide) in a dose of 250 mg per
day during 8 weeks to overweight women did not cause
any significant changes in inflammatory markers [49]. In
another study, taking zinc supplement (30 mg per day of
zinc sulphate) during 6 months did not cause any signifi-
cant change in CRP in women with pre-diabetes [10].
However, magnesium-zinc-calcium-vitamin D supple-
mentation for 12 weeks in women with PCOS was asso-
ciated with a decrease in CRP levels [14]. Combined
magnesium-zinc-calcium-vitamin D supplementation in
another similar study caused a significant decrease in hs-
CRP and MDA, and an increase in TAC without any sig-
nificant changes in nitric oxide (NO) and GSH levels
[50]. A recent study reported that combined magnesium
and zinc supplementation (250 mg/day of magnesium
oxide plus 220mg/day zinc sulfate) to women with
PCOS during 12 weeks improved hs-CRP and TAC al-
though no significant effects were been seen on NO,
MDA and GSH levels [13]. However, these discrepancy
between studies may be due to differences in sampling
method, study duration, age ranges, dosage of magnesium
and zinc used, the characteristics of participants, differences
between intervention and control groups, cross-over design
or parallel design, and dietary intake of participants.
Magnesium is assumed to have anti-inflammatory
properties caused by its antagonist effects to calcium
which contributes to inflammation, transmembrane ion
transport, and protein synthesis [21]. Magnesium also
increases the production of NO and prostacyclins [22].
Zinc seems to have effects on hemostasis by influencing
coagulation and platelet aggregation [23]. Zinc deficiency
has impact on calcium channels and calcium uptake de-
fects [24]. Also, second-messenger performance probably
originates from unusual sulfhydryl redox states in the
membrane channel protein having an impact on CVD
[24]. Moreover, zinc may decrease inflammation and
oxidative damage having effects on hemostasis by in-
fluencing coagulation and platelet aggregation [23],
and reducing the activity of calcium channels [24].
Magnesium may have anti-inflammatory effects be-
cause of its antagonist effects to the calcium which
contributes to inflammation, transmembrane ion
transport, and protein synthesis [21] and increased
production of prostacyclins [22].
Effects of magnesium plus zinc supplementation on
depression and anxiety
This study indicated that combined magnesium and zinc
supplementation to patients with CHD and T2DM dur-
ing 12 weeks improved BDI and BAI scores. The preva-
lence of depression and anxiety in CHD subjects is high
and it is responsible for an increased risk of mortality in-
fluencing healthy lifestyle and increased motivation to
stay healthy and compliance to therapy [51]. A study
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using food frequency questionnaire and general health
questionnaire reported a reverse correlation between
dietary magnesium intake and depression and anxiety
[52]. A review suggested that zinc deficiency due to re-
duced zinc absorption and low intake of dietary zinc is
prevalent in mood disorders and that zinc supplementa-
tion can have beneficial impacts [53, 54]. Nonetheless,
Fard et al. showed that supplementation with 27 mg per
day zinc sulfate or 320 mg/day magnesium sulfate did
not improve postpartum anxiety and depressive symp-
toms after 8 weeks [55]. In another study by Nikseresht
et al. administration of combined 30 mg/kg zinc chlor-
ide, 30 mg/kg magnesium chloride and 50 mg/kg
thiamine-HCl in mice with postpartum depression
symptoms improved these symptoms and anxiety-like
behavior [56]. Zinc and magnesium act as cofactors and
contribute significantly to synthesis and release of neu-
rotransmitters and thereby can have antidepressant and
anxiolytic effects [57]. For example, zinc and magnesium
prevent binding of N-methyl-D-aspartate receptors to
glutamate and may be associated with antidepressant
and anxiolytic effects [58].
Strength and study limitation
The present study has a number of strengths. The
current study focused on novel questions using a ran-
domized, double-blind, placebo-controlled trial. The
findings of improved FPG, insulin, total nitrite, HDL-
cholesterol, CRP, TAC levels, BDI and BAI score in the
intervention group in the current study are interesting,
but need to be confirmed in a larger study. Another
strength of this study was the low dropout rate. This
study has some limitations. The most important one is
relatively small number of patients despite the fact that
the power analysis showed that the number of partici-
pants is sufficient. In addition, due to funding limita-
tions, gene expression related to insulin, lipid, oxidative
damage and inflammation in patients with T2DM and
CHD could not be evaluated.
Conclusions
The combined magnesium and zinc supplementation
during 12 weeks had beneficial effects on FPG, insu-
lin, total nitrite, HDL-cholesterol, CRP, TAC levels,
BDI and BAI score. However, it had no significant
impact on other metabolic variables in patients with
T2DM and CVD. This suggests that magnesium and
zinc co-supplementation may be beneficial for pa-
tients with T2DM and CHD. Further research is
needed on more patients and for longer periods to
determine the safety of magnesium and zinc co-
supplementation.
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